Renal transplantationOutcomeBasiliximab or Antithymocyte Globulin for Induction Therapy in Kidney Transplantation: A Meta-analysis
Section snippets
Search Strategy
On August 16, 2009, PubMed/MEDLINE (1966 to August 2009), Cochrane Collaboration's Central Register of Controlled Trials (Issue 3, 2009), EMBASE.com (1966 to August 2009), and the China Biological Medicine Database (CBMdisc; 1978 to August 2009) were searched, using the validated Cochrane highly sensitive search strategy for RCTs. The search terms employed were “simulect,” “basiliximab,” “interleukin 2 receptor antibody,” “antithymocyte globulin,” “ATG,” “kidney transplantation,” and “renal
Descriptions of Studies
By using the search key terms listed earlier, 264 articles were identified. Eighteen articles were retrieved for full-text assessment after titles and abstracts were reviewed. Twelve articles were excluded because they were not randomized controlled trials or were repeat publication. Finally, six trials3, 4, 9, 10, 11, 12 including 853 patients were included in this meta-analysis. The main features of the six trials are shown in Table 1.
Primary Outcomes
In this report, we considered biopsy-proven rejection,
Discussion
Induction therapy is specific therapy given at the time of transplantation to lower the incidence of acute rejection and thus improve allograft survival. Some agents, such as ATG/ALG, OKT3, daclizumab, basiliximab, and Alemtuzumab have been tried in clinical induction therapy.1, 4, 13 Among them, ATG and basiliximab are most widely used. Currently, almost 70% of kidney transplant recipients receive induction therapy with either basiliximab or ATG.14 Many studies and meta-analysis demonstrated a
References (14)
- et al.
Comparison of single bolus ATG and basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen
Transpl Immunol
(2008) - et al.
Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy
Am J Transplant
(2002) - et al.
ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results
Transplant Proc
(2003) - et al.
Long-term results of monoclonal anti-IL2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation
Transplant Proc
(2006) - et al.
Alemtuzumab (alemtuzumab 1H) induction therapy in cadaveric kidney transplantation—efficacy and safety at five years
Am J Transplant
(2005) Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review
BioDrugs
(2005)- et al.
Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation
BioDrugs
(2003)
Cited by (35)
Heterogeneous Manifestations of Posttransplant Lymphoma in Renal Transplant Recipients: A Case Series
2021, Transplantation ProceedingsEffectiveness of Thymoglobulin Induction Therapy in Kidney Transplant From Deceased Donor With Mild to Moderate Acute Kidney Injury
2019, Transplantation ProceedingsCitation Excerpt :Basiliximab and Thymoglobulin are the most commonly used agents for induction therapy of KT, and there have been many comparative studies on their efficacy and safety. There was no significant difference in efficacy between the 2 groups in the general randomized controlled trials, but Thymoglobulin was better in acute rejection in study of high-risk patients [12–16]. It is now common practice in the transplant community to select induction therapy on the basis of risk-benefit consideration.
Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis
2018, Transplantation ProceedingsImmunosuppressive Therapy in Transplantation
2016, Nursing Clinics of North AmericaCitation Excerpt :Even though induction therapy provides clear improvement in patient and graft outcomes, infection and malignancy, particularly cytomegalovirus and lymphoma respectively, remain major concerns following administration of induction therapy.6,13,14,19,21 Basiliximab seems to result in fewer infections compared with other agents.5 Further data are needed to determine whether basiliximab is superior to R-ATG in the reduced incidence of neoplasm.
This work is attributed to the Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Ministry of Health, and Key Laboratory of Ministry of Education.